Physician profile

Katherine Chiyu Wang

Hematology & Oncology · Dallas, TX

NPI 1669494134

$188,192.81

in general payments reported to CMS, 2019-2025

62 companies · $18K in 2025

The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$42,357.50
Honoraria$14,575.00
Food and Beverage$5,419.69
Travel and Lodging$5,246.03
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$2,195.00
Education$82.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $38,884.54 2019-2024 Opdivo
Immunocore Limited $35,398.47 2022-2025 Kimmtrak
Astrazeneca Pharmaceuticals Lp $24,828.61 2019-2025 Imfinzi, Lynparza, Calquence
Incyte Corporation $11,790.19 2019-2025 Jakafi
Genzyme Corporation $9,305.28 2020-2022
Janssen Scientific Affairs, LLC $9,049.45 2020-2024 Imbruvica, Talvey, Tecvayli
Verastem, INC. $7,920.00 2019
Lilly USA, LLC $7,424.18 2022-2024 Verzenio, Retevmo, Jaypirca
Kite Pharma, INC. $6,738.12 2019-2025 Yescarta
Karyopharm Therapeutics INC. $3,569.07 2020-2024 Xpovio
Tesaro, INC. $3,312.20 2019
Daiichi Sankyo INC. $2,972.16 2022-2025 Enhertu, Datroway
Seagen INC. $2,957.41 2019-2023 Tukysa
Gilead Sciences, INC. $2,886.50 2021-2025 Trodelvy
Abbvie INC. $2,877.53 2020-2025
Show all 62 companies
CompanyGeneral paymentsYearsTop products
Array Biopharma INC $1,956.70 2022-2025 Braftovi, Mektovi, Lorbrena
Janssen Biotech, INC. $1,878.83 2019-2025 Rybrevant, Carvykti, Tecvayli
Celgene Corporation $1,750.51 2019-2025 Reblozyl, Pomalyst
Chiesi USA, INC. $1,605.00 2020
Blueprint Medicines Corporation $1,525.88 2021-2022
Astrazeneca Uk Limited $1,334.54 2019
Cti Biopharma Corp. $1,250.00 2022
Beigene USA, INC. $1,164.53 2022-2025 Brukinsa
Bayer Healthcare Pharmaceuticals INC. $1,025.16 2019-2025
Eusa Pharma (US) LLC $900.00 2020
Astellas Pharma US INC $520.56 2021-2024 Vyloy
Beigene, Ltd. $450.00 2020
Merck Sharp & Dohme LLC $267.42 2019-2025 Keytruda, Lynparza, Keytruda Qlex
Pfizer INC. $236.86 2019-2025
Novartis Pharmaceuticals Corporation $216.81 2019-2025
Regeneron Healthcare Solutions, INC. $174.05 2023-2025 Libtayo, Lynozyfic
Glaxosmithkline, LLC. $171.01 2024-2025 Ojjaara, Blenrep, Penmenvy
Amgen INC. $170.08 2019-2024 Lumakras
Athenex Pharmaceutical Division, LLC $164.23 2019
Adc Therapeutics America, INC. $150.93 2023-2025
Ipsen Biopharmaceuticals, INC $123.64 2019
Janssen Pharmaceuticals, INC $117.77 2021-2023 Xarelto
Clovis Oncology, INC. $116.66 2019
Cardinal Health 110 LLC $100.00 2020
Takeda Pharmaceuticals U.S.A., INC. $95.92 2023-2025 Iclusig, Fruzaqla, Ninlaro
Jazz Pharmaceuticals INC. $92.01 2025
Geron Corporation $71.05 2025 Rytelo
Legend Biotech USA INC. $67.19 2025 Carvykti
Emd Serono, INC. $63.58 2025
Sobi, INC $57.66 2024-2025
Genmab U.S., INC. $48.15 2025 Epkinly
Eisai INC. $46.96 2023-2024
Beone Medicines USA, INC. $42.44 2025 Brukinsa, Tevimbra
Aveo Pharmaceuticals, INC. $42.42 2024
Puma Biotechnology, INC. $33.82 2023-2025
Genentech USA, INC. $29.98 2025 Xolair
Tempus Ai, INC $28.78 2024
Tersera Therapeutics LLC $27.88 2019
Deciphera Pharmaceuticals INC. $27.47 2025 Romvimza, Qinlock
Syndax Pharmaceuticals, INC. $24.53 2025
Stemline Therapeutics INC. $23.80 2024 Elzonris
Epizyme, INC. $21.97 2022
Boehringer Ingelheim Pharmaceuticals, INC. $16.23 2024 Gilotrif
Iovance Biotherapeutics, INC. $15.15 2025 Amtagvi
180 Medical, INC. $14.76 2019
Servier Pharmaceuticals LLC $13.33 2024
Apo-Pharma USA, INC. $2.85 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Katherine Chiyu Wang

$188,192.81

in general payments reported 2019-2025

Years
2019-2025
Top company
E.R. Squibb & Sons, L.L.C.
Context
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).

https://glasscript.com/doctor/75177/katherine-chiyu-wang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.